- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2016–2021 · research · R01
Humanized bone marrow-like model to study patient-derived myeloma xenografts
Richard Groen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2020 · fellowship · F31
Structure-Function Analysis of a Novel Inhibitory Mechanism for Pro-Apoptotic BAK
Zachary Joel Hauseman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · grant · PRCRP
Therapeutic Strategies for MYCN-Amplified Neuroblastoma
Nathanael Gray · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2016–2021 · research · R01
Identifying causal variants and genes underlying breast cancer risk loci
Matthew L Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R50
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
Gregory Howard Bird · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R50
Immunogenomic analytical approaches for research and clinical applications
Sachet Ashok Shukla · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2020 · fellowship · F31
Structure-Function Analysis of a Novel Inhibitory Mechanism for Pro-Apoptotic BAK
Zachary Joel Hauseman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
Anthony G Letai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · career development · K99
Investigating the role of RBM10-regulated alternative splicing in lung tumorigenesis
Peter S. Choi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K08
The mechanism of DNA damage and chromothripsis from chromosome segregation errors
Alexander Spektor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R01
USP7 inhibitors for the treatment of multiple myeloma
Sara J Buhrlage · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R50
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
Gregory Howard Bird · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
A. Thomas Look · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · research · R21
Biophysical and Mechanistic Determinants for Cancer Cell Import of Hydrocarbon-Stapled Peptides
Loren David Walensky · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · career development · K99
Investigating the role of RBM10-regulated alternative splicing in lung tumorigenesis
Peter S. Choi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · grant · DP1
Epigenetic plasticity in tumor initiation and evolution
Bradley Evan Bernstein · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R01
Humanized bone marrow-like model to study patient-derived myeloma xenografts
Richard Groen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2020 · research · R01
Organizational Approaches to Total Worker Health for Low-Income Workers
Glorian C Sorensen · Dana-Farber Cancer Institute · funded by National Institute for Occupational Safety and Health
2016–2027 · research · R01
Axonal transport and chemotherapy induced peripheral neuropathy
Rosalind A. Segal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · career development · K99
Statistical Methods for the Normalization and Quantification of Single-Cell RNA-Sequencing Data
Stephanie Carinne Hicks · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R21
Barriers to Hospice and Palliative Care Utilization Among Adolescent and Young Adult Cancer Patients Living in Poverty
Jennifer W Mack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R01
USP7 inhibitors for the treatment of multiple myeloma
Sara J Buhrlage · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R01
Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer
Christopher J Sweeney · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
Rosalind A. Segal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Identifying causal variants and genes underlying breast cancer risk loci
Matthew L Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · career development · K99
Statistical Methods for the Normalization and Quantification of Single-Cell RNA-Sequencing Data
Stephanie Carinne Hicks · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K07
Video Informed Consent Tools to Improve Care for Patients With Advanced Pancreatic Cancer
Andrea C Enzinger · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K08
Determining the Role of BCOR Mutations in Myeloid Malignancies
Robert Coleman Lindsley · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
Jean Zhao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Neuroimmune mechanisms of depression in adults with HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
Jean Zhao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma
Kenneth C. Anderson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · grant · Continuing Grant
Collaborative Research: Rational Design of Anticancer Drug Combinations using Dynamic Multidimensional Theory
Levi Garraway · Dana-Farber Cancer Institute · funded by National Science Foundation
2016–2020 · fellowship · F31
Structure-Function Analysis of a Novel Inhibitory Mechanism for Pro-Apoptotic BAK
Zachary Joel Hauseman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · program · P01
Targeting Immunogenicity to the MPER Hinge and C-helix for BNAb Elicitation
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · cooperative agreement · U01
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection
Brian Matthew Wolpin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
A. Thomas Look · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K07
Video Informed Consent Tools to Improve Care for Patients With Advanced Pancreatic Cancer
Andrea C Enzinger · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2017 · grant · PRCRP
Development of Epitope-Focused Tumor Vaccine to Prevent Escape from Immune Surveillance by the NKG2D Pathway
Soumya Badrinath · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
